Related Experiment Video
Updated: Oct 18, 2025
Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening
Published on: September 5, 2018
A novel design of microfluidic platform for metronomic combinatorial chemotherapy drug screening based on 3D tumor
Sharanya Sankar1, Viraj Mehta1, Subhashini Ravi1
1Regenerative Medicine and Stem Cell Laboratory (RMS), Department of Biomedical Engineering, Indian Institute of Technology Hyderabad, Telangana, India.
Abstract:
For treating cancer at various stages, chemotherapy drugs administered in combination provide better treatment results with lower side effects compared to single-drug therapy. However, finding the potential drug combinations has been challenging due to the large numbers of possible combinations from approved drugs and the failure of in vitro 2D well plate-based cancer models. 3D spheroid-based high-throughput microfluidic platforms recapitulate some of the important features of native tumor tissue and offer a promising alternative to evaluate the combinatory effects of the drugs. This study develops a novel polydimethylsiloxane (PDMS) based microfluidic design with a dynamic environment and strategically placed U-shaped wells for testing all seven possible combinations (three single-drug treatments, three pairwise combinations, treatment with all three drugs) of three chemotherapy drugs (Paclitaxel, Vinorelbine, and Etoposide) on lung tumor spheroids. The design of U-shaped wells has been validated with computational results. Firstly, we test all combinations of drugs on the conventional well plate in static conditions with 3D tumor spheroids. Based on static drug testing results, we show a proof-of-concept by testing the most effective drug combination on the microfluidic device in a dynamic environment. The concentration of the drugs used in combination falls below the maximum tolerated dose (MTD) of the individual drugs, towards low dose metronomic (LDM) chemotherapy. LDM combinatorial chemotherapy identified in this study can potentially lower toxicity and provide better treatment results in cancer patients. The device can be further used to culture patient-specific tumor spheroids and identify synergistic drug combinations for personalized medicine.
Insights
This study introduces a novel microfluidic device for testing chemotherapy drug combinations on 3D lung tumor spheroids. It identifies effective low-dose metronomic (LDM) combinations to improve cancer treatment and reduce toxicity.
Area of Science:
- Biomedical Engineering
- Cancer Research
- Drug Discovery
Background:
- Chemotherapy drug combinations improve cancer treatment outcomes but identifying effective combinations is challenging.
- Traditional 2D cell culture models fail to accurately predict in vivo drug efficacy.
- 3D spheroid models and microfluidic platforms offer more physiologically relevant environments for drug testing.
Purpose of the Study:
- To develop and validate a novel polydimethylsiloxane (PDMS) microfluidic platform for evaluating chemotherapy drug combinations.
- To test all possible combinations of Paclitaxel, Vinorelbine, and Etoposide on lung tumor spheroids.
- To identify synergistic low-dose metronomic (LDM) chemotherapy combinations with reduced toxicity.
Main Methods:
- A novel PDMS microfluidic device with U-shaped wells was designed and computationally validated.
- Three chemotherapy drugs (Paclitaxel, Vinorelbine, Etoposide) were tested in all combinations on 3D lung tumor spheroids.
- Drug efficacy was evaluated under static conditions in well plates and then in a dynamic microfluidic environment.
Main Results:
- The microfluidic device design was validated using computational fluid dynamics.
- The study identified effective drug combinations at concentrations below the maximum tolerated dose (MTD).
- A proof-of-concept demonstrated the efficacy of a selected drug combination in the dynamic microfluidic system.
Conclusions:
- The developed microfluidic platform enables efficient testing of multiple chemotherapy drug combinations.
- Low-dose metronomic (LDM) combinatorial chemotherapy shows potential for improved efficacy and reduced toxicity in cancer treatment.
- The platform can be adapted for personalized medicine by using patient-specific tumor spheroids to identify tailored drug combinations.
